# Study of INBRX-109 in Conventional Chondrosarcoma

> **NCT04950075** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Inhibrx Biosciences, Inc** · enrollment: 206 (actual)

## Conditions studied

- Conventional Chondrosarcoma

## Interventions

- **DRUG:** INBRX-109
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04950075
- **Lead sponsor:** Inhibrx Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-23
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-12
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04950075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04950075, "Study of INBRX-109 in Conventional Chondrosarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04950075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*